GlassScriptPhysician profile
Allison Hutcherson
NPI 1104208883
$999.92
in general payments reported to CMS, 2019-2025
16 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.75 · 2022: $115 · 2023: $293 · 2024: $37.63 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.05 | 2021-2025 | |
| Viiv Healthcare Company | $250.44 | 2022-2025 | Rukobia, Dovato, Cabenuva |
| Gilead Sciences, INC. | $110.75 | 2025 | Biktarvy |
| Shionogi INC | $48.99 | 2022 | |
| Insmed, INC. | $45.54 | 2023 | Arikayce |
| Octapharma USA, INC. | $40.00 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Paratek Pharmaceuticals, INC. | $37.91 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $34.34 | 2021-2025 | Pifeltro |
| Aimmune Therapeutics, INC. | $33.93 | 2025 | Vowst |
| Theratechnologies INC. | $31.05 | 2021-2023 | Egrifta, Trogarzo |
| Grifols USA, LLC | $23.75 | 2025 | Gamunex-C |
| Pfizer INC. | $20.88 | 2021 | |
| Emd Serono, INC. | $20.72 | 2021 | |
| Ferring Pharmaceuticals INC. | $19.91 | 2023 | Rebyota |
| Janssen Biotech, INC. | $13.07 | 2023 | Symtuza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hutcherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.